Revvity, Inc. (NYSE:RVTY) Shares Bought by UniSuper Management Pty Ltd

UniSuper Management Pty Ltd grew its stake in shares of Revvity, Inc. (NYSE:RVTY - Free Report) by 24.9% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 18,399 shares of the company's stock after acquiring an additional 3,671 shares during the period. UniSuper Management Pty Ltd's holdings in Revvity were worth $2,054,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Elo Mutual Pension Insurance Co grew its holdings in Revvity by 18.8% during the 4th quarter. Elo Mutual Pension Insurance Co now owns 13,019 shares of the company's stock worth $1,453,000 after acquiring an additional 2,059 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. boosted its stake in shares of Revvity by 2.1% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 3,382,338 shares of the company's stock valued at $384,234,000 after purchasing an additional 69,034 shares in the last quarter. Korea Investment CORP increased its holdings in Revvity by 74.8% during the fourth quarter. Korea Investment CORP now owns 54,665 shares of the company's stock valued at $6,101,000 after buying an additional 23,400 shares during the period. Murphy & Mullick Capital Management Corp bought a new position in Revvity in the fourth quarter worth approximately $107,000. Finally, Vanguard Group Inc. lifted its holdings in Revvity by 1.1% during the fourth quarter. Vanguard Group Inc. now owns 14,290,211 shares of the company's stock worth $1,594,930,000 after buying an additional 156,679 shares during the period. Hedge funds and other institutional investors own 86.65% of the company's stock.

Remove Ads

Insider Buying and Selling

In related news, insider Tajinder S. Vohra sold 5,492 shares of the firm's stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $116.81, for a total transaction of $641,520.52. Following the sale, the insider now directly owns 19,652 shares of the company's stock, valued at $2,295,550.12. This trade represents a 21.84 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Joel S. Goldberg sold 15,170 shares of Revvity stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $126.73, for a total value of $1,922,494.10. Following the transaction, the insider now owns 33,400 shares of the company's stock, valued at approximately $4,232,782. This represents a 31.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.68% of the stock is currently owned by corporate insiders.

Revvity Stock Performance

RVTY stock traded down $5.12 during midday trading on Thursday, reaching $101.60. The stock had a trading volume of 473,863 shares, compared to its average volume of 946,893. The firm has a fifty day simple moving average of $114.20 and a two-hundred day simple moving average of $116.84. Revvity, Inc. has a 52-week low of $97.32 and a 52-week high of $129.50. The company has a debt-to-equity ratio of 0.41, a quick ratio of 3.03 and a current ratio of 3.60. The stock has a market cap of $12.21 billion, a PE ratio of 45.97, a P/E/G ratio of 3.82 and a beta of 1.06.

Revvity (NYSE:RVTY - Get Free Report) last announced its quarterly earnings data on Friday, January 31st. The company reported $1.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.37 by $0.05. Revvity had a return on equity of 7.68% and a net margin of 9.81%. During the same period in the previous year, the business earned $1.25 earnings per share. As a group, equities research analysts anticipate that Revvity, Inc. will post 4.94 EPS for the current year.

Revvity Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, May 9th. Stockholders of record on Friday, April 18th will be issued a $0.07 dividend. This represents a $0.28 annualized dividend and a dividend yield of 0.28%. The ex-dividend date of this dividend is Thursday, April 17th. Revvity's dividend payout ratio (DPR) is currently 12.67%.

Analyst Ratings Changes

Several research analysts have recently commented on RVTY shares. Bank of America raised Revvity from a "neutral" rating to a "buy" rating and set a $138.00 price target for the company in a research report on Friday, December 13th. Sanford C. Bernstein downgraded shares of Revvity from an "outperform" rating to a "market perform" rating and set a $130.00 target price for the company. in a report on Friday, January 10th. Barclays raised their price target on shares of Revvity from $135.00 to $140.00 and gave the company an "overweight" rating in a report on Monday, February 3rd. KeyCorp boosted their price objective on shares of Revvity from $132.00 to $145.00 and gave the stock an "overweight" rating in a research note on Monday, February 3rd. Finally, Raymond James restated an "outperform" rating and issued a $145.00 target price (up from $140.00) on shares of Revvity in a research note on Monday, February 3rd. Four investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $136.25.

Revvity Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.